nCounter® Breast Cancer 360™

Helping Your Research

Want a system that provides a unique 360° view of gene expression for the breast tumor, microenvironment, and immune response? If yes, then you have found the right product. The Human nCounter Breast Cancer 360 panel and data analysis report helps researchers quickly decode the complexities of breast cancer biology, develop novel breast cancer gene signatures, and categorize disease heterogeneity using 48 biological signatures including signatures based upon the validated PAM50 and Tumor Inflammation Signature (TIS) assays. Get the most out of your panel by quickly distilling a large amount of data into actionable signatures measuring variables crucial to breast tumor-immune interaction.

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

How It Works

The content included in the Breast Cancer 360 panel allows for a more comprehensive measurement of biological variables crucial to tumor progression and response to a wide range of treatments. Research signatures are enriched with potentially predictive genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis.

01:

Highly Curated Content:

Expertly curated, comprehensive content includes 776 genes across 23 key breast cancer pathways and processes, 10 research focused signatures and 30 novel signatures measuring important tumor and immune activities.

02:

Comprehensive Coverage:

Expanded evaluation of breast cancer subtypes including: PAM50 Signature, TNBC, and Claudin-Low Signature.

03:

Interactive, Flexible Report:

The Interactive Breast Cancer 360 data analysis report provides insight into 48 signatures across 13 categories measuring biological variables crucial to breast cancer tumor biology.

You can access validated signatures like PAM50, Tumor Inflammation Signature (TIS), Risk of Recurrence (ROR)/Genomic Risk. Analyze your data by survival, response or grouping variables, or drill down into individual sample variability. Analyze clinical variables by TNBC/PAM50 subtype or variables of your choosing.

04:

Publication Ready Data:

The report generates figures, statistical outputs, methods for your publication, or poster presentation.

Hear more about Breast Cancer 360 panel from our scientists- Video Decode Heterogeneity with the Breast Cancer 360™ Panel The Breast Cancer 360™ Data Analysis Report Video The Breast Cancer 360™ Data Analysis Report

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Breast Cancer 360 Biological Signatures

Breast Cancer 360 Pathways and Processes

PAM50 and TIS Signatures

Product Specifications

Product Comparison

Catalog Information

Breast Cancer 360 Biological Signatures

Breast Cancer 360 Pathways and Processes

Includes expertly curated 776 genes across 23 categories of breast cancer tumor biology to support the evaluation of pathways and process, as well as novel signature development.

PAM50 and TIS Signatures

Content included in the Breast Cancer 360 panel allows for a more comprehensive measurement of biological variables crucial to tumor progression and response to a wide-range of treatments. Research signatures are enriched with potentially predictive genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis.

48 signatures including two analytically validated signatures- PAM50^1,2 and Tumor Inflammation Signature³
10 research-focused signatures and 30 novel signatures measuring important tumor and immune activities
adapted to decode breast cancer biology in concert

Analytically Validated Signatures

PAM50 Signature^1,2

Included with the Breast Cancer 360 panel is the PAM50 Signature. This 50-gene signature measures a gene expression profile that allows for the classification of breast cancer into four biologically distinct subtypes and a prognostic score.

PAM50 Subtype
- Luminal A
- Luminal B
- HER2-Enriched
- Basal-like
Prosigna Score / Risk of Recurrence

Tumor Inflammation Signature³

Included with the Breast Cancer 360 panel is the Tumor Inflammation Signature. This 18-gene signature measures activity known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade³.

Includes 4 areas of immune biology used to determine peripherally suppressed immune response and the identification of “hot” or “cold” tumors
- Antigen Presenting Cells
- T Cell/NK presence
- IFNγ Biology
- T Cell Exhaustion
Tissue-of-origin agnostic (Pan-cancer)
Potential surrogate for PD-L1 and mutational load in research setting⁴

View publication and video.

Product Specifications

Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Catalog Information

Related Resources

See All Resources

Product Bulletin Breast Cancer 360 – Product Bulletin

Report BC360 Demo Data Analysis Report

Report BC360 Time Series Demo Data Analysis Report

Report BC360 TNBC Demo Data Analysis Report

Report Viewing nCounter 360 Web Reports

Publications

View All Publications

Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer.

PURPOSE: Perineural invasion (PNI), a common occurrence in oral squamous cell carcinomas, is associated with poor survival. Consequently, these tumors are treated aggressively.

Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients.

Background: Pancreatic cancer (PC) is a malignancy with a poor prognosis and high mortality. Surgical resection is the only “curative” treatment.

Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer.

Neuronal nerve processes in the tumor microenvironment were highlighted recently. However, the origin of intra-tumoral nerves remains poorly known, in part because of technical difficulties in tracing nerve fibers via conventional histological preparations.